Literature DB >> 21289050

Inhibition of renal caveolin-1 reduces natriuresis and produces hypertension in sodium-loaded rats.

John J Gildea1, Brandon A Kemp, Nancy L Howell, Robert E Van Sciver, Robert M Carey, Robin A Felder.   

Abstract

Renal dopamine receptor function and ion transport inhibition are impaired in essential hypertension. We recently reported that caveolin-1 (CAV1) and lipid rafts are necessary for normal D(1)-like receptor-dependent internalization of Na-K-ATPase in human proximal tubule cells. We now hypothesize that CAV1 is necessary for the regulation of urine sodium (Na(+)) excretion (U(Na)V) and mean arterial blood pressure (MAP) in vivo. Acute renal interstitial (RI) infusion into Sprague-Dawley rats of 1 μg·kg⁻¹·min⁻¹ fenoldopam (FEN; D(1)-like receptor agonist) caused a 0.46 ± 0.15-μmol/min increase in U(Na)V (over baseline of 0.29 ± 0.04 μmol/min; P < 0.01). This increase was seen in Na(+)-loaded rats, but not in those under a normal-sodium load. Coinfusion with β-methyl cyclodextrin (βMCD; lipid raft disrupter, 200 μg·kg⁻¹·min⁻¹) completely blocked this FEN-induced natriuresis (P < 0.001). Long-term (3 day) lipid raft disruption via continuous RI infusion of 80 μg·kg⁻¹·min⁻¹ βMCD decreased renal cortical CAV1 expression (47.3 ± 6.4%; P < 0.01) and increased MAP (32.4 ± 6.6 mmHg; P < 0.001) compared with vehicle-infused animals. To determine whether the MAP rise was due to a CAV1-dependent lipid raft-mediated disruption, Na(+)-loaded rats were given a bolus RI infusion of CAV1 siRNA. Two days postinfusion, cortical CAV1 expression was decreased by 73.6 ± 8.2% (P < 0.001) and the animals showed an increase in MAP by 17.4 ± 2.9 mmHg (P < 0.01) compared with animals receiving scrambled control siRNA. In summary, acute kidney-specific lipid raft disruption decreases CAV1 expression and blocks D(1)-like receptor-induced natriuresis. Furthermore, chronic disruption of lipid rafts or CAV1 protein expression in the kidney induces hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289050      PMCID: PMC3074998          DOI: 10.1152/ajprenal.00380.2010

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  47 in total

1.  Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism.

Authors:  Leslie J Salomone; Nancy L Howell; Helen E McGrath; Brandon A Kemp; Susanna R Keller; John J Gildea; Robin A Felder; Robert M Carey
Journal:  Hypertension       Date:  2006-11-20       Impact factor: 10.190

Review 2.  Caveolae as organizers of pharmacologically relevant signal transduction molecules.

Authors:  Hemal H Patel; Fiona Murray; Paul A Insel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Na+/H+ exchanger NHE3 activity and trafficking are lipid Raft-dependent.

Authors:  Rakhilya Murtazina; Olga Kovbasnjuk; Mark Donowitz; Xuhang Li
Journal:  J Biol Chem       Date:  2006-04-27       Impact factor: 5.157

4.  Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity.

Authors:  Robin A Felder; Pedro A Jose
Journal:  Nat Clin Pract Nephrol       Date:  2006-11

5.  Hydrogen peroxide causes uncoupling of dopamine D1-like receptors from G proteins via a mechanism involving protein kinase C and G-protein-coupled receptor kinase 2.

Authors:  Mohammad Asghar; Anees Ahmad Banday; Riham Z Fardoun; Mustafa F Lokhandwala
Journal:  Free Radic Biol Med       Date:  2005-09-08       Impact factor: 7.376

6.  Co-localization and interaction of b0,+-type amino acid transporter 1 (BAT1) with caveolin-1 in rat kidney.

Authors:  Jin-Oh Kwak; Hyun-Woo Kim; Sun-Mi Jung; Joon Ho Song; Seong Bin Hong; Kwang-Jin Oh; Chang-Bo Ko; Seok Ho Cha
Journal:  J Nephrol       Date:  2005 Nov-Dec       Impact factor: 3.902

7.  Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney.

Authors:  Y Bai; S Ye; R Mortazavi; V Campese; N D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2006-11-22

8.  Immunohistochemical study on caveolin-1alpha in regenerating process of tubular cells in gentamicin-induced acute tubular injury in rats.

Authors:  Yoshihide Fujigaki; Masanori Sakakima; Yuan Sun; Tetsuo Goto; Naro Ohashi; Hirotaka Fukasawa; Takayuki Tsuji; Tatsuo Yamamoto; Akira Hishida
Journal:  Virchows Arch       Date:  2007-04-27       Impact factor: 4.064

9.  Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice.

Authors:  Sebastian Albinsson; Yulia Shakirova; Anna Rippe; Maria Baumgarten; Bert-Inge Rosengren; Catarina Rippe; Rupert Hallmann; Per Hellstrand; Bengt Rippe; Karl Swärd
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-07-11       Impact factor: 3.619

10.  Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice.

Authors:  Takahisa Murata; Michelle I Lin; Yan Huang; Jun Yu; Phillip Michael Bauer; Frank J Giordano; William C Sessa
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

View more
  11 in total

1.  A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics.

Authors:  Rene Baudrand; Mark O Goodarzi; Anand Vaidya; Patricia C Underwood; Jonathan S Williams; Xavier Jeunemaitre; Paul N Hopkins; Nancy Brown; Benjamin A Raby; Jessica Lasky-Su; Gail K Adler; Jinrui Cui; Xiuqing Guo; Kent D Taylor; Yii-Der I Chen; Anny Xiang; Leslie J Raffel; Thomas A Buchanan; Jerome I Rotter; Gordon H Williams; Luminita H Pojoga
Journal:  Metabolism       Date:  2015-09-12       Impact factor: 8.694

2.  Newly Developed Dopamine D3 Receptor Antagonists, R-VK4-40 and R-VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats.

Authors:  Chloe J Jordan; Bree A Humburg; Eric B Thorndike; Anver Basha Shaik; Zheng-Xiong Xi; Michael H Baumann; Amy Hauck Newman; Charles W Schindler
Journal:  J Pharmacol Exp Ther       Date:  2019-09-27       Impact factor: 4.030

3.  Lipid rafts are required for effective renal D1 dopamine receptor function.

Authors:  Andrew C Tiu; Jian Yang; Laureano D Asico; Prasad Konkalmatt; Xiaoxu Zheng; Santiago Cuevas; Xiaoyan Wang; Hewang Lee; Momina Mazhar; Robin A Felder; Pedro A Jose; Van Anthony M Villar
Journal:  FASEB J       Date:  2020-04-07       Impact factor: 5.191

Review 4.  Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Authors:  Richard Van Krieken; Joan C Krepinsky
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

5.  Role of caveolin 1 in AT1a receptor-mediated uptake of angiotensin II in the proximal tubule of the kidney.

Authors:  Xiao C Li; Victor Gu; Elise Miguel-Qin; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-27

6.  Interaction among Caveolin-1 genotypes (rs3807987/rs7804372), H. pylori infection, and risk of gastric cancer in a Chinese population.

Authors:  Ye Zhang; Xue-jun Hu; Lu-lu Zhang; Li-ping Sun; Yuan Yuan; Xiu-juan Qu; Yun-peng Liu
Journal:  Tumour Biol       Date:  2013-09-25

7.  Elucidating the Role of Lipid Rafts on G Protein-Coupled Receptor Function in the Mouse Kidney: An In Vivo Approach.

Authors:  Laureano D Asico; Selim Rozyyev; Annabelle M Crusan; Pedro A Jose; Van Anthony M Villar
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Renal Dopamine Receptors and Oxidative Stress: Role in Hypertension.

Authors:  Jian Yang; Van Anthony M Villar; Pedro A Jose; Chunyu Zeng
Journal:  Antioxid Redox Signal       Date:  2020-05-29       Impact factor: 8.401

Review 9.  The Role of the Renal Dopaminergic System and Oxidative Stress in the Pathogenesis of Hypertension.

Authors:  Waleed N Qaddumi; Pedro A Jose
Journal:  Biomedicines       Date:  2021-02-01

10.  Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.

Authors:  Rene Baudrand; Nidhi Gupta; Amanda E Garza; Anand Vaidya; Jane A Leopold; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Jose R Romero; Jonathan Williams; Joseph Loscalzo; Gail K Adler; Gordon H Williams; Luminita H Pojoga
Journal:  J Am Heart Assoc       Date:  2016-09-28       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.